Thank you for standing by and welcome to the Alnylam Pharmaceuticals Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, today’s conference call is being recorded. I would now like to turn the conference over to the company. Please go ahead.

Good morning. I am Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Akshay Vaishnaw, President; and Jeff Poulton, Chief Financial Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page for website, investors.alnylam.com/events. During today’s call, as outlined on Slide 2, Yvonne will offer introductory remarks and provide some general context. Tolga will provide an update on our global commercial progress, Akshay will review early pipeline updates and clinical progress, and Jeff will review our financials and guidance, followed by a summary of upcoming milestones before we open the call to your questions. I’d like to remind you that this call will contain remarks from turning on Alnylam’s future expectations, plans, prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recently quarterly report on file with the SEC. In addition, any forward-looking statements represent our views as only as the date of this report and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I’d like to turn the call over to Yvonne. Yvonne?

Thanks, Christine, and thank you everyone for joining the call today. We are very pleased with the results delivered in the third quarter, both commercially and with our pipeline. Commercially, this is the first full quarter of our AMVUTTRA launch since the U.S. approval back in June, which drove 30% growth in the U.S. for the TTR franchise compared to quarter two. Clinically, the TTR franchise is a high life as well. We presented positive results for the APOLLO-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy, validating the therapeutic hypothesis that RNAi-mediated silencing of TTR has the potential to result in a disease-modifying impact on the cardiac manifestations of ATTR amyloidosis. We are delighted with the totality of these results and we look forward to submitting a supplemental NDA for ONPATTRO by year end. This also gives us increased confidence in the HELIOS-B Phase 3 outcome study of vutrisiran in ATTR amyloidosis with cardiomyopathy, which is on track for top line results in early 2024. Our earlier stage programs advance as well with positive results presented from the Phase 2 study of cemdisiran in patients with IgA nephropathy as well as preliminary data in patients from the ongoing Phase 1 study of ALN-HSD in development for the treatment of NASH. In the coming quarters, we expect to have more exciting updates from our pipeline, including results for potential biannual dose regimen for vutrisiran preliminary Phase 1 results and healthy volunteers for ARN XDH, an investigational RNAi therapeutic for the treatment of gout. Completion of enrollment in the KARDIA-2 Phase 2 study of zilebesiran and initiation of a Phase 1 healthy volunteer study of ALN-TTRscO4, for which we filed a CTA earlier this month. This execution is in line with our focus on these key drivers for Alnylam’s growth over the next several years. Firstly, the potential near-term expansion of our TTR franchise opportunity, where we aim to become a global leader in delivering impactful and highly differentiated medicines for patients. Second our expansion beyond rare diseases and to prevalent diseases. And the third growth driver for the company comes from our sustainable innovation engine comprised of new platform enhancements, opportunities with extrahepatic delivery and our ability to find new genetically validated targets, which can drive further pipeline expansion to 2025 and beyond. We believe all of this positions us well to deliver on our Alnylam piece of it by ‘25 goal, making Alnylam a top biotech company, developing and commercializing transformative medicines for rare and prevalent diseases for patients around the world driven by a high-yielding pipeline of first and/or best-in-class product candidates from our organic product engine, all while delivering exceptional financial results. With that, let me now turn the call over to Tolga for a review of our commercial performance. Tolga?

Thanks, Yvonne and good morning everyone. Q3 was a strong quarter for our commercial portfolio, with 9% quarter-over-quarter growth driven by a strong launch of AMVUTTRA in the U.S., as Yvonne highlighted. While still early, we are encouraged by several signs indicating that AMVUTTRA is expanding the size of the opportunity for our hATTR-PN franchise. I will have more details to share on this shortly. The strengthening of the U.S. dollar continues to impact product revenues from our international operations as ONPATTRO, GIVLAARI, and OXLUMO Q3 product sales each experienced FX headwinds compared with the prior quarter and prior year periods. With initial sales of AMVUTTRA which are now reflected in our quarterly financial results, moving forward, we will highlight our results for ONPATTRO and AMVUTTRA on a combined franchise basis. We saw robust growth in our TTR franchise in Q3, achieving $170 million in global net product revenues for ONPATTRO and AMVUTTRA, representing an 11% increase compared with the second quarter and a solid 41% growth compared with Q3 2021. At the end of Q3 over 2,580 patients were on commercial ONPATTRO or AMVUTTRA treatment worldwide, up from over 2,400 patients at the end of the second quarter, representing a steady 8% quarterly patient growth. In the U.S., combined sales of ONPATTRO and AMVUTTRA increased a robust 30% versus the second quarter and were primarily impacted by the following and 19% increase in demand growth, which was driven by the strength of the initial AMVUTTRA patient uptake, more than offsetting the decrease in patients on ONPATTRO that switched AMVUTTRA. In total for the quarter, 180 patients initiated AMVUTTRA treatment with over 40% representing new patients for Alnylam and the balance representing patients switching from ONPATTRO. Initial AMVUTTRA launch inventory stocking in the distribution channel increased growth an additional 11%…

Thanks, Tolga and good morning everyone. I will start with our efforts in ATTR amyloidosis, where we are advancing two clinical stage product candidates Patisiran and Vutrisiran. Whilst ONPATTRO is currently approved in multiple markets around the world to treat the polyneuropathy associated with hereditary AT amyloidosis, we are committed to expanding the product’s label for the treatment of cardiomyopathy in both hereditary and wild-type ATTR amyloidosis patients. To this end, we are excited to have recently presented positive results from the APOLLO-B Phase 3 study, where Patisiran achieved a statistically significant and clinically meaningful improvement relative to placebo in the 6-minute walk test at 12 months, the primary endpoint of the study. It also achieved a statistically significant and clinically meaningful improvement relative to placebo at 12 months on the Kansas City Cardiomyopathy Questionaire, the study’s first secondary endpoint and a key measure of patient self-reported health status and quality of life. Furthermore, Patisiran demonstrated an acceptable tolerability profile and we are very encouraged by the overall safety profile of Patisiran. Collectively, we believe these efficacy results validate the therapeutic hypothesis that RNAi-mediated silencing of TTR has the potential to result in a disease-modifying impact on cardiac manifestations of ATTR amyloidosis. With these results in hand, we remain on track to submit a supplemental NDA filing for review by the FDA by the end of this year with the goal of obtaining regulatory approval in the U.S. making this medicine available to patients with ATTR amyloidosis with cardiomyopathy as rapidly as possible. Also advancing Vutrisiran which is delivered by a quarterly subcutaneous injection and amongst is AMVUTTRA to treat the polyneuropathy of hATTR amyloidosis. AMVUTTRA was approved based on results from the HELIOS-A Phase 3 study. That study includes an ongoing randomized treatment expansion where we are evaluating a…

Thanks, Akshay, and good morning, everyone. I’m pleased to be presenting a summary of Alnylam’s Q3 2022 financial results and an update on our full year guidance. Starting with a summary of our P&L results for Q3 2022. A Total product revenues for the quarter were $232 million or 39% growth versus Q3 2021. It is also worth noting that year-over-year growth in combined product revenues was held back by approximately 10% due to the foreign exchange impact of a strengthening U.S. dollar and given that approximately 45% of our product revenues are generated via sales in international markets. Net revenue from collaborations for the third quarter was approximately $29 million, representing a 45% increase compared with Q3 2021, primarily due to an increase in revenue recognized in connection with our collaboration agreement with Regeneron and contributed to an increase in reimbursable activities under our Research Services arrangement in addition to an increase in revenue recognized associated with partnership clinical trial activities. Our non-GAAP R&D expenses increased 6% in the third quarter 2022 compared to the same period in 2021, primarily due to increased compensation-related expenses as a result of increased employee headcount and an increase in development expenses, primarily associated with the ramp-up in enrollment in the KARDIA-1 and KARDIA-2 zilebesiran Phase 2 studies offset by decreased clinical batches manufactured during the quarter. Our non-GAAP SG&A expenses increased 33% in the third quarter of 2022 compared to the same period in 2021 primarily due to increased headcount and other strategic investments in support of our AMVUTTRA launch and other corporate purposes. Our non-GAAP operating loss for Q2 2022 was $130 million representing an $18 million improvement compared with Q2 2021, driven by strong top line growth, offset by more moderate growth in operating expenses. Finally, we ended the quarter…

Thank you, Jeff. Operator, we will now open the call for your questions. [Operator Instructions]

Thank you. [Operator Instructions] Our first question comes from Maury Raycroft Jefferies. Your line is open.

Hi. Good morning, and thanks for taking my question. I was wondering if you can talk about whether you’ve gotten any feedback from FDA on APOLLO-B data and what the NDA package would contain? And also, if you can talk about confidence around your primary endpoint P value and whether FDA has provided any specific comments on this?

Thanks for that question. Maury. I mean, clearly, we were delighted with the results from our APOLLO-B study where we deliver clinically meaningful and significant benefits across the 6-minute walk test and KCCQ, which are important measures actually for patients in terms of how they function and feel and we’ve got good safety and numerical reduction test. So we are very confidence with the package of data that we have supporting this indication holistically, particularly given the small size and short duration of the study, actually, perhaps you can follow-up on our regulatory progress.

Yes. So thanks, Maury, and thanks, Yvonne. I mean, I think you addressed at the high level, the key positives that came out of the study that reinforces that therapeutics can have a significant impact, we believe, in ATT amyloidosis, including in the cardiomyopathy. We’re proceeding to file the supplemental NDA by the end of the year, as we’ve said. We’re confident in this package the points that Yvonne outlined as the file goes under review, the FDA was get a safety update, 180-day safety update during review, so we will be providing that, of course. And we will be very responsive to any questions they have. And so that’s as much as I can say. At this point in time. But we’ve shared the data across two meetings at ISA and HFSA had extremely strong and positive responses from investigates KOLs and others. And so we are excited for that.

That’s great. So moving forward expeditiously. Thank you, Maury. Next question.

Thank you. Our next question comes from Salveen Richter. Your line is open.

Is interim. Did the outcomes analysis of APOLLO-B impact your thinking on treated or placebo separation here? And how much time do you save? Thank you.

Actually, I think that’s one for you.

So actually repeat the full question. I think talking about the outcomes analysis, but the line is not brilliant. So we didn’t quite catch the second half of your question. Could you repeat it for us?

Sure. Could you explain the factors you considered when deciding not to conduct the HELIOS-B interim? I’m just wondering whether the outcomes analysis of APOLLO-B impact your thinking on treated placebo separation and how much time you save here?

The question is around thinking behind not progressing the interim analysis.

Yes, I mean, Salveen, as you intimate, the positive data out of pole significantly increase our confidence and belief that the design and conduct of HELIOS-B is the right test of the hypothesis that vutrisiran can help patients with ATTR cardiomyopathy. So we feel quite involved of looking at all the detailed data, most of which we’ve shared already at these international meetings, but there are others. And so that was one major factor. The second was we obviously want to have the best data associated with vutrisiran to make it a best-in-class product, hopefully, for patients with ATTR cardiomyopathy. The best way to do that is to preserve alpha and not mess around with the statistics, which obviously, if you do an interim, then that has a significant downstream conference on how on both the statistics for the final readout in early ‘24. And thirdly is just the speed at which everything is moved which we’re delighted by. So the fact that HELIOS-B actually overenrolled that it did, means it’s such a narrow time frame between any putative interim and any potential approval thereof versus the full readout in early ‘24 and hopefully getting a great label in serving patients with ATTR cardiomyopathy.

That’s great actually. Thank you very much. Next question.

Thank you. Our next question comes from Tazeen Ahmad of Bank of America. Your line is open.

Hi, good morning, guys. Thanks so much for taking my question. Maybe, Yvonne can you just clarify whether your team has already met with FDA for your pre-sNDA meeting regarding the APOLLO-B results yet? Or is that still to come? And then secondly, do you have any expectations about whether or not an AdCom would be needed to review this filing. It is the second indication proposed for an already approved drug, but I just wanted to get your latest thoughts on that? Thanks.

Yes. Thanks, Tazeen. I mean, as you know, we don’t comment on regulatory interactions. I think I actually covered this in an earlier question, we’re very confident with the package that we have supporting this indication, and we’re moving forward as planned with a submission later this year. That’s about all I can say on the topic. But thanks for the question.

Thank you. Our next question comes from Eliana Merle of UBS. Your line is open.

Hey, thanks so much for taking the question. Just another one in terms of thinking about HELIOS-B as well as the potential uptake in cardiomyopathy, could you help us understand how you interpret the data in tafamidis combination? And what this could potentially mean in terms of uptake in, say, tafamidis progressors or combination use in the real world commercially. And any initial feedback say you are hearing initially? I know it’s early, but just curious your thoughts.

Right. So I think there may be kind of two parts of the question. I think one actually may be starting off with new perspectives around data and combination with [indiscernible], maybe talk to give some perspectives on how you see things in the commercial?

Thank you, Yvonne. Vis-a-vis your, question Eliana on the family subgroup concomitant with Patisiran. Just to step back, this was a, I think, a large robust study that considered the real-world population out there. The majority of whom don’t have any drug right now, about 75% of the study was on placebo and no background therapy at about 25% of patients had background to [indiscernible]. I refer you to our HFS a output and Dr. Mara’s very eloquent discussion of why it’s a little bit of a full there and just to use a phrase to cut into small subgroup analysis that really are not powered and the study was not designed to tell we fool ourselves. And again, Dr. Maria explained and discussed all this very well. I thought it HFSA. So the overall readout of the study, I think, was robust and excellent impacting patients functionality via the fixed in walk distance and the quality of life, lots of internal consistency in the data. So this is a strong package and we’re delighted with it. I appreciate the interest of subgroups, so that’s really know what the study was poured to read out.

Yes, I thought that just generally or factors around how the commercial.

Yes. Just to build on Akshay’s point, it would be premature for us to comment anything specific on without the label. But what we can tell you is if you just look at the numbers since the launch of tafamidis, the diagnosis rate went up by 10x and we certainly anticipate that to continue. This is a highly devastating disease. Across the U. S. and ex-U.S., there is about 250,000 to 300,000 patients suffer from this devastating disease. And what we know is those patients that are a lot of untreated patients and those patients who continue to progress on TAF. So we believe our upcoming therapies if they are approved, will be a very attractive option, both for physicians and obviously for patients.

Thank you. So absolutely lots of medical needs still the – these patients unfortunately. Next question please.

Thank you. Our next question comes from Ritu Baral of Cowen. Your line is open.

Good morning, guys. Thanks for taking the question. Yvonne or Akshay, should we be expecting priority review on the sNDA just given what you and your regulatory consultancy as the unmet need in TTR cardiomyopathy. And can you just also remind us when the last interaction you had with FDA was in the past, obviously, not forward-looking. And if there is been any significant turnover in the review team or senior members in the review division since then.

Thanks, Ritu. So another question about the regulatory outlook here actually in terms of expectations with respect to priority of and another question really just asking us to comment on our progress with regulatory interactions. So I think you’ve sort of answered the question, but maybe you can reiterate the point.

Yes. I mean, I think it, thanks for the question. As you know, we don’t discuss the back and forth the regulators. I will reiterate what I said earlier, that we’re confident in this data package, we’re on track to file the supplemental NDA by the end of the year and the priority review, well, that’s the FDA’s decision, and they have to evaluate the pros and cons of this therapy and the data package we’ve submitted. And we will eagerly await their decision, but there is not much more I can put.

And Ritu can we comment on review team turnover. I think that’s what the FDA has managed and we’re not really in a position to speak to that. Thank you. Next question.

Thank you. Our next question comes from Jessica Fye of JPMorgan. Your line is open.

Hey, guys. Good morning. Thanks for taking my questions. Did you have a pre-NDA meeting yet for the ONPATTRO cardiomyopathy filing or if not, do you expect to?

Yes. Thanks for the question. I mean again, I think there is lots of interest around this. The most important thing is that we obviously have lots of back and forth regulators across all our programs. And let me just reiterate that we will file the supplemental NDA by the end of the year for this program based on everything we have discussed so far on this call and in many other settings. So, thanks for the question.

Thanks Akshay. Next question please.

Thank you. Our next question comes from the line of David Lebowitz of Citi. Your line is open.

Thank you very much for taking my question. When you look at the ONPATTRO, the AMVUTTRA new patient start forms, I noticed that the number of new patients percentage uptick from what was announced in the first quarter of launch, I think we from about a third to nearly 50%. Could you comment on what the expectations for new patients to be coming to market is and what that might – how that might impact growth of the overall franchise relative to what ONPATTRO would have done without the presence of AMVUTTRA?

Yes. No, that’s a great question. I mean we are particularly pleased with the performance of our TTR franchise, especially the progress of the AMVUTTRA launch in the U.S., and we are seeing a kind of great dynamic, with approximately half of new patients and switches. And I think you made the point about a TTR franchise, which I would like to underscore. I think we now really have a TTR franchise and we expect to be able to grow the PN market, encourage earlier treatment given the very effective regimen of AMVUTTRA. But Tolga, do you want to add some more color maybe to how you are seeing the outlook for the TTR franchise?

No, absolutely, Yvonne. Look, early signs of U.S. AMVUTTRA launch is a good testament to the overall TTR franchise future. Our TTR franchise grew by 30% versus last quarter, driven mainly by AMVUTTRA. Two-thirds of this growth was really demand. In our view, early signs of performance really confirm three key beliefs. One is the fine available treatments, there is a significant unmet need and the role of AMVUTTRA and its attractive product profile will continue to increase growth. That’s going to be important. And also, we do have the strong foundational capabilities that we build over time across customer-facing capabilities that will allow us to continue expand this growth. So, we are really excited about this. We are still scratching the surface in terms of diagnosis and treatment. There are 10,000 to 15,000 patients in the U.S. that suffer from this condition. We believe AMVUTTRA’s product profile will be a very nice fit to that treatment regimen.

Thanks Tolga. Next question please.

Our next question comes from the line of Gena Wang of Barclays. Your line is open.

Thank you for taking my questions. Sorry, I will ask APOLLO-B question again. I think because there are quite some questions were raised on its approvability since it’s only one study and then there is no outcome data. So, maybe if you could refresh our memory, the history of APOLLO-B study. So, basically, how study was designed and was it aligned with the FDA?

Yes. Akshay, that’s clearly for you.

Yes. Thanks Gena. I think we have discussed much of this on other calls, but let me just reiterate, Gena, that I think this is – I am losing track a little bit say for seven Phase 3 study or seven Phase 3 studies we have negotiated with the FDA and other regulators around the world. All our work is in collaboration with guidance from regulators. We have four Alnylam products approved based on that excellent set of dialogues and the relationships we have and understanding how regulators are trying to guide us. This product and this trial was no different from that. And so if any credibility or confidence is derived from our prior performance I would like you to apply it here. Now, in the specifics here, when APOLLO was done, and we all remember the conversations, those of you that were involved then, the cardiac data we got a subgroup data from APOLLO were very promising. And the FDA said, yes, that is the case, and we have discussed that before. And based on that, they guided us that we should do a separate study in a cardiomyopathy population. And with that conversation and collaboration, the design that you see in APOLLO-B resulted. And so this study was done in close collaboration with regulators, and we are grateful for the guidance, and we are very happy with the outcome where clearly, we have shown the impact on patient functionality and quality of life, which are two cornerstones of FDA base of approval of drugs. Safety looks very encouraging to us, too. And then finally, on the monetary front, you will recall that four patients on placebo rather on patisiran and 10 on placebo. So, that’s encouraging, although it’s a small number. So, this package, we believe, is rather strong for a trial that was designed in collaboration with regulators. And so we are looking forward to filing the NDA.

Thank you.

Next question.

Thank you. Our next question comes from the line of Paul Matteis of Stifel. Your line is open.

Hey. Thanks so much. I was really interested in your comments in the press release and in the prepared remarks on drug positioning related to the Inflation Reduction Act and kind of broader drug pricing risk. And to that point, you just filed a CTA for a once annual TTR knockdown drug. How do you think about positioning that and kind of balancing Stargardt versus this potentially just being a next-gen and TTR cardiomyopathy and also enabling you to maintain premium pricing beyond a decade in that space? Thanks so much.

Thank you for the question here. I think look, the inflation reduction is a significant shift in Medicare and how the Federal Government regulates our industry. We are supportive of the new Part D patient out-of-pocket caps, but we have considerable concerns about a couple of other aspects of the legislation. Clearly, the first is around concerns a small molecule medicines, face negotiated Medicare reimbursement rates only 9 years after approval compared to 13 years for monoclonal antibodies. I think very pertinent to us in the near-term is that while the exemptions in the Inflation Reduction Act from Medicare price negotiation for a drug that has a single orphan drug indication, they are now this incentive to pursuing the approval of drugs that in additional indications. Look, we are still digesting the legislation. But as you pointed out, in the meantime, besides the patisiran Phase 3 study in Stargardt disease, as we consider options for the best path forward. I would like to just kind of note three points really. One is that we remain excited actually by the opportunity for an RNAi-mediated TTR lowering method as a potential therapy in patients with Stargardt disease. We think it’s an important unmet medical need. And the second, I think you touched on it when you talked about TTRsc04. As a platform company, we really have the opportunity to continuously innovate and bring optionality to how we think about developing our medicines. And I think TTRsc04 is another TTR lowering program that we are moving forward, which we are very excited about. I think the other point that I would like to make, which I think is quite important is just to remind everybody that Vutrisiran actually has orphan disease that we mentioned for TTR amyloidosis, be it polyneuropathy or cardiomyopathy. So, as with many other companies, we are reflecting on the implications that that’s relatively new legislation on how we think about our portfolio. But as a company, we actually think we are very well positioned given our platform and our ability to continue to innovate around our medicines.

Okay. The next question?

Our next question comes from the line of Gary Nachman of BMO. Your line is open.

Hi. Good morning. If you end up getting the ONPATTRO of APOLLO-B approval, let’s say, end of next year, but then you will be bumping up against the Vutrisiran HELIOS-B data in early ‘24. How much of an impact do you think that might have on your launch of ONPATTRO in CM when physicians will be anticipating this other important data set. I know it’s a bit early thinking about the launches, but given the timing of these, I was curious to get some of your early thoughts on that. Thanks.

Well, so I will just start off by saying that the reason why we progress ONPATTRO in the cardiomyopathy indication just a level of unmet medical need, that’s the patients who continue to progress despite various therapies. And really, we took the opportunity with ONPATTRO to try to bring a near-term solution for these patients, whilst we continue to develop Vutrisiran in our HELIOS-B study. And as you pointed out, we will have those results shortly at the beginning of 2024. So, we think that we are able to meet the needs of patients in the near-term hopefully with the approval of ONPATTRO and CM. And then as we progress HELIOS-B going forward and even more attractive regimen for these patients shortly afterwards. But maybe Tolga, you can comment on how we are thinking about the launch of ONPATTRO with the opportunity hopefully of bringing Vutrisiran to these patients in the medium-term.

Yes. No, I think you summarized perfectly, Yvonne. All I would add is there is a big unmet need. There are patients who are currently on available treatments that are continuing to progress. And to your point, we want to make an alternative treatment available as quickly as possible so we can actually meet those needs and also continue to build our capabilities for the larger indication. We are obviously very pleased with the capabilities that we have built based on what we are actually able to demonstrate with AMVUTTRA CM [ph] launch. And as we continue to expand the indication, we believe our experience with the CM is going to help us to have even a stronger launch with AMVUTTRA CM, if it’s approved.

Thanks Tolga, that’s great. So again, the sort of TTR franchise approach, which we think will be important for patients and our commercial performance going forward.

Next question.

Thank you. Our next question comes from Luca Issi of RBC Capital.

Hey. Great. Thanks so much for taking my question. Maybe one on the pipeline, if I may. So, maybe on APP, kind of any additional color on why the readout has been pushed out? And maybe bigger picture, can you level set expectations to-date the next year? Wht reduction in CSF APP alpha and beta would you consider it meaningful? And maybe what’s the earliest we could possibly see functional data for that data set? Thanks so much.

Great. Thank you, Luca, for a question on APP. Look, we are clearly excited about the potential for RNAi therapeutics and addressing CNS diseases. This is the first one out of the gate and we are progressing kind of very well, but thoughtfully as Akshay described in his introductory remarks. But actually, maybe you can speak to the data that we are expecting after the ongoing study.

Yes. The crucial data, I think first and foremost is safety. This is our first candidate in central nervous system. So, that’s a keen interest. The study is progressing well. So, we are very comfortable so far. Beyond that, obviously, there is lots of interest in the biomarker outlook. And so we will be looking for APP knockdown and the fragments therapeutic trail from APP changes in those of the CNS APP. And in addition to that, there is going to be important PK because, again, it’s the first time we have injected that have to [indiscernible]. So, those are the key data points in the short-term that we will be looking at and looking forward to reporting in early ‘23.

Absolutely. And as we move forward in APP, we are able to demonstrate the impact on patients with – anyone with Alzheimer’s disease. The quarter opens up the opportunity for a whole host of other devastating CNS supporters. So, a very important program for us, we are progressing well. Thank you for the question.

Next question please.

Thank you. Our next question comes from Joseph Stringer of Needham & Company. Your line is open.

Hi. Good morning. Thanks taking our question. A question on AMVUTTRA start forms in the percentage sourced from new prescribers. I think this quarter you have around 17%, that was similar to 20% from your last update. Do you sort of see this continuing and fairly stable in that 15% to 20% range going forward, or how do you see that going forward? Thank you.

Tolga, that’s clearly a question for you. How do you see the percentage of new prescribers going forward?

Yes. Look, I mean I am glad you have highlighted that. We are really excited about sort of how we are displaying those strong foundational capabilities that we have been able to build from diagnosis all the way to access support. One of those excitements is we see a healthy balance of physicians, both from academic centers and community specialists, start prescribing this medication. And as you pointed out, another important metric is the new prescribers. We see a steady increase of this new specialist around 20% month-after-month being added to the prescriber base. And as a result of that, we also see patients are treated a bit younger, a sign that patients are getting diagnosed and obviously, they are getting the AMVUTTRA treatment. Another important metric that we also see and where we are obviously going to pay a lot of attention to this is our start forms to treatment rates, despite having a temporary J-code, it’s been similar to ONPATTRO. And again, thanks to our good access support, VBAs and our price parity strategy. So, because of those elements, we believe we are going to continue to see a good expansion of new prescribers and net new patients for AMVUTTRA that’s going to drive the TTR franchise to the next level.

Super. Thank you very much.

And I think we have got time for one more question.

Thank you. Our next question comes from Myles Minter of William Blair. Your line is open.

Hi. Thanks for squeezing me in. Just on OXLUMO actually, just with the recent FDA label expansion. Are you expecting like a significant amount of warehouse advanced PH1 patients. And I guess, how are you thinking about growing that franchise moving forward, considering it looks somewhat flat over the past quarters? Thanks.

Tolga, do you want…?

Look, GIVLAARI [ph] is a devastating disease and we are very pleased to be able to actually provide important treatment for these ultra-rare disease patients. LMHC has been a great addition – we do see a good addition to our data suite of data that we have. We see a good group of patients, both from pediatric and as adults level as well as various progressive stage of their diseases. It eliminates is simply another important element that will allow the prescribers to be able to prescribe this medicine to a broad range of patients that suffer from this ultra-rare disease. End of Q&A:

Look, we have had a great quarter. We really are based in our commercial performance and we are seeing strong growth in patients on therapy across all of our commercial portfolio. So, I am certainly very pleased with our performance. So, thank you everyone for joining us on this call. Great progress in the third quarter of 2022, we talked about our strong commercial results, but also we are pleased with how we are advancing our diverse pipeline programs that are in development. A lot of excitement ahead, cashless on deck in the coming months and we of course, look forward to updating you along the way as we continue to deliver on our near and long-term goals. So, thank you everybody and have a great day.

Thank you. Ladies and gentlemen, this does conclude today’s conference. Thank you all for participating. You may now disconnect. Have a great day.